{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:31:33Z","timestamp":1793284293493,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.xcrm.2024.101417","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T15:28:01Z","timestamp":1707751681000},"page":"101417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effector functions are required for broad and potent protection of neonatal mice with antibodies targeting HSV glycoprotein D"],"prefix":"10.1016","volume":"5","author":[{"given":"Matthew D.","family":"Slein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iara M.","family":"Backes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callaghan R.","family":"Garland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha S.","family":"Kelkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Leib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-3476","authenticated-orcid":false,"given":"Margaret E.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101417_bib1","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1016\/S2214-109X(16)30362-X","article-title":"First estimates of the global and regional incidence of neonatal herpes infection","volume":"5","author":"Looker","year":"2017","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.xcrm.2024.101417_bib2","series-title":"Predictors of Morbidity and Mortality in Neonates with Herpes Simplex Virus Infections","author":"Whitley","year":"2010"},{"key":"10.1016\/j.xcrm.2024.101417_bib3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/jpids\/piab105","article-title":"Neonatal Herpes Simplex Virus Infection: Epidemiology and Outcomes in the Modern Era","volume":"11","author":"Melvin","year":"2022","journal-title":"J.\u00a0Pediatric Infect. Dis. Soc."},{"key":"10.1016\/j.xcrm.2024.101417_bib4","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa1003509","article-title":"Oral Acyclovir Suppression and Neurodevelopment after Neonatal Herpes","volume":"365","author":"Kimberlin","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101417_bib5","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1056\/NEJMra0807633","article-title":"Maternal and Neonatal Herpes Simplex Virus Infections","volume":"361","author":"Corey","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101417_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/jama.289.2.203","article-title":"Effect of Serologic Status and Cesarean Delivery on Transmission Rates of Herpes Simplex Virus From Mother to Infant","volume":"289","author":"Brown","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2024.101417_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/infdis\/158.1.109","article-title":"Changing Presentation of Herpes Simplex Virus Infection in Neonates","volume":"158","author":"Whitley","year":"1988","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101417_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.semperi.2007.01.003","article-title":"Herpes Simplex Virus Infections of the Newborn","volume":"31","author":"Kimberlin","year":"2007","journal-title":"Semin. Perinatol."},{"key":"10.1016\/j.xcrm.2024.101417_bib9","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/infdis\/160.5.770","article-title":"Neonatal Antibody-Dependent Cellular Cytotoxic Antibody Levels Are Associated with the Clinical Presentation of Neonatal Herpes Simplex Virus Infection","volume":"160","author":"Kohl","year":"1989","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101417_bib10","doi-asserted-by":"crossref","first-page":"S950","DOI":"10.1093\/clind\/13.Supplement_11.S950","article-title":"Role of Antibody-Dependent Cellular Cytotoxicity in Neonatal Infection with Herpes Simplex Virus","volume":"13","author":"Kohl","year":"1991","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101417_bib11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1056\/NEJM198701293160503","article-title":"Low Risk of Herpes Simplex Virus Infections in Neonates Exposed to the Virus at the Time of Vaginal Delivery to Mothers with Recurrent Genital Herpes Simplex Virus Infections","volume":"316","author":"Prober","year":"1987","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101417_bib12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/261505a0","article-title":"Postexposure serum prophylaxis of neonatal herpes simplex virus infection of mice","volume":"261","author":"Baron","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101417_bib13","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1128\/iai.37.3.1132-1137.1982","article-title":"Protection against lethal challenge of BALB\/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2","volume":"37","author":"Balachandran","year":"1982","journal-title":"Infect. Immun."},{"key":"10.1016\/j.xcrm.2024.101417_bib14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1128\/iai.34.1.192-199.1981","article-title":"Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease","volume":"34","author":"Dix","year":"1981","journal-title":"Infect. Immun."},{"key":"10.1016\/j.xcrm.2024.101417_bib15","volume":"91","author":"Wang","year":"2017","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101417_bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1128\/iai.38.1.168-174.1982","article-title":"Use of monoclonal antibodies for analysis of antibody-dependent immunity to ocular herpes simplex virus type 1 infection","volume":"38","author":"Rector","year":"1982","journal-title":"Infect. Immun."},{"key":"10.1016\/j.xcrm.2024.101417_bib17","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1128\/jvi.53.3.944-948.1985","article-title":"Role of antibody in primary and recurrent herpes simplex virus infection","volume":"53","author":"Simmons","year":"1985","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101417_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/02713688709020086","article-title":"Passive immunization with monoclonal antibodies against herpes simplex virus glycoproteins protects mice against herpetic ocular disease","volume":"6","author":"Metcalf","year":"1987","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.xcrm.2024.101417_bib19","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1128\/JVI.01924-10","article-title":"Impact of Valency of a Glycoprotein B-Specific Monoclonal Antibody on Neutralization of Herpes Simplex Virus","volume":"85","author":"Krawczyk","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101417_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.959603","article-title":"Monoclonal antibody therapy of herpes simplex virus: An opportunity to decrease congenital and perinatal infections","volume":"13","author":"Backes","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101417_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12350","article-title":"Mouse and human FcR effector functions","volume":"268","author":"Bruhns","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.xcrm.2024.101417_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01743-21","article-title":"Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity","volume":"12","author":"Goldberg","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.xcrm.2024.101417_bib23","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.immuni.2021.03.009","article-title":"A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus","volume":"54","author":"Gunn","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2024.101417_bib24","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.molmed.2016.09.002","article-title":"Modulating Antibody Functionality in Infectious Disease and Vaccination","volume":"22","author":"Gunn","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.xcrm.2024.101417_bib25","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220110","article-title":"Maternally transferred mAbs protect neonatal mice from HSV-induced mortality and morbidity","volume":"219","author":"Backes","year":"2022","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2024.101417_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1006\/viro.1996.0011","article-title":"Protection of Nude Mice by Passive Immunization with a Type-Common Human Recombinant Monoclonal Antibody against HSV","volume":"215","author":"Sanna","year":"1996","journal-title":"Virology"},{"key":"10.1016\/j.xcrm.2024.101417_bib27","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.drudis.2016.03.003","article-title":"Novel therapeutic investigational strategies to treat severe and disseminated HSV infections suggested by a deeper understanding of in\u00a0vitro virus entry processes","volume":"21","author":"Clementi","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.xcrm.2024.101417_bib28","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1074\/jbc.M009483200","article-title":"High Resolution Mapping of the Binding Site on Human IgG1 for Fc\u03b3RI, Fc\u03b3RII, Fc\u03b3RIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fc\u03b3R","volume":"276","author":"Shields","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.xcrm.2024.101417_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07008-0","article-title":"Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model","volume":"9","author":"Bailey","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101417_bib30","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/08820130802608238","article-title":"Functional Characterization of N297A, A Murine Surrogate for low-Fc Binding Anti-Human CD3 Antibodies","volume":"38","author":"Chao","year":"2009","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.xcrm.2024.101417_bib31","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101417_bib32","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1074\/jbc.M116.767749","article-title":"Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice","volume":"292","author":"Lo","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.xcrm.2024.101417_bib33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13238-017-0473-8","article-title":"IgG Fc engineering to modulate antibody effector functions","volume":"9","author":"Wang","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.xcrm.2024.101417_bib34","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0092-8674(94)90115-5","article-title":"FcR gamma chain deletion results in pleiotrophic effector cell defects","volume":"76","author":"Takai","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101417_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe3349","article-title":"Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates","volume":"13","author":"Hangartner","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101417_bib36","doi-asserted-by":"crossref","first-page":"12149","DOI":"10.1128\/JVI.76.23.12149-12161.2002","article-title":"Noninvasive Bioluminescence Imaging of Herpes Simplex Virus Type 1 Infection and Therapy in Living Mice","volume":"76","author":"Luker","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101417_bib37","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1099\/0022-1317-2-3-357","article-title":"Characterization of Herpes Simplex Virus Strains Differing in their Effects on Social Behaviour of Infected Cells","volume":"2","author":"Ejercito","year":"1968","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.xcrm.2024.101417_bib38","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2221247120","article-title":"Complement contributes to antibody-mediated protection against repeated SHIV challenge","volume":"120","author":"Goldberg","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101417_bib39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"Hessell","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101417_bib40","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41467-022-28250-7","article-title":"Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis","volume":"13","author":"Spencer","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101417_bib41","doi-asserted-by":"crossref","first-page":"18002","DOI":"10.1073\/pnas.2008190117","article-title":"Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti\u2013HIV-1 IgG1 antibodies in\u00a0vivo","volume":"117","author":"Wang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101417_bib42","doi-asserted-by":"crossref","first-page":"18754","DOI":"10.1073\/pnas.2008236117","article-title":"Fc-mediated effector function contributes to the in\u00a0vivo antiviral effect of an HIV neutralizing antibody","volume":"117","author":"Asokan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101417_bib43","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.cell.2021.02.026","article-title":"Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection","volume":"184","author":"Winkler","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101417_bib44","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201993","article-title":"Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in\u00a0vivoIn\u00a0vivo efficacy of anti\u2013SARS-CoV-2 antibodies","volume":"218","author":"Sch\u00e4fer","year":"2021","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2024.101417_bib45","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41577-022-00813-1","article-title":"Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection","volume":"23","author":"Zhang","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2024.101417_bib46","doi-asserted-by":"crossref","first-page":"9422","DOI":"10.1073\/pnas.0703498104","article-title":"Monoclonal antibody-mediated enhancement of dengue virus infection in\u00a0vitro and in\u00a0vivo and strategies for prevention","volume":"104","author":"Goncalvez","year":"2007","journal-title":"Proc. Natl.\u00a0Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101417_bib47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy Results of a Trial of a Herpes Simplex Vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101417_bib48","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.vaccine.2013.08.066","article-title":"Current status and prospects for development of an HSV vaccine","volume":"32","author":"Johnston","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101417_bib49","doi-asserted-by":"crossref","first-page":"469","DOI":"10.21775\/cimb.041.469","article-title":"Alphaherpesvirus Vaccines","volume":"41","author":"Aschner","year":"2021","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.xcrm.2024.101417_bib50","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1086\/315208","article-title":"Limited Antibody-Dependent Cellular Cytotoxicity Antibody Response Induced by a Herpes Simplex Virus Type 2 Subunit Vaccine","volume":"181","author":"Kohl","year":"2000","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101417_bib51","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.282.4.331","article-title":"Recombinant Glycoprotein Vaccine for the Prevention of Genital HSV-2 InfectionTwo Randomized Controlled Trials","volume":"282","author":"Corey","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2024.101417_bib52","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/infdis\/jiac284","article-title":"Failure of Herpes Simplex Virus Glycoprotein D Antibodies to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines","volume":"226","author":"Mahant","year":"2022","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101417_bib53","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/infdis\/jiac067","article-title":"Neutralizing Antibody Kinetics and Immune Protection Against Herpes Simplex Virus 1 Genital Disease in Vaccinated Women","volume":"227","author":"Belshe","year":"2023","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101417_bib54","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/infdis\/jiu177","article-title":"Better Neutralization of Herpes Simplex Virus Type 1 (HSV-1) Than HSV-2 by Antibody From Recipients of GlaxoSmithKline HSV-2 Glycoprotein D2 Subunit Vaccine","volume":"210","author":"Awasthi","year":"2014","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101417_bib55","article-title":"A non-neutralizing glycoprotein B monoclonal antibody protects against herpes simplex virus disease in mice","volume":"133","author":"Kuraoka","year":"2022","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2024.101417_bib56","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","article-title":"Affinity of human IgG subclasses to mouse Fc gamma receptors","volume":"9","author":"Dekkers","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.xcrm.2024.101417_bib57","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1126\/science.1118948","article-title":"Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding","volume":"310","author":"Nimmerjahn","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101417_bib58","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1128\/CMR.10.3.419","article-title":"Experimental investigation of herpes simplex virus latency","volume":"10","author":"Wagner","year":"1997","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.xcrm.2024.101417_bib59","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1128\/jvi.56.2.489-494.1985","article-title":"Specificity of Fc receptors induced by herpes simplex virus type 1: comparison of immunoglobulin G from different animal species","volume":"56","author":"Johansson","year":"1985","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101417_bib60","doi-asserted-by":"crossref","first-page":"8933","DOI":"10.1128\/JVI.72.11.8933-8942.1998","article-title":"The Herpes Simplex Virus gE-gI Complex Facilitates Cell-to-Cell Spread and Binds to Components of Cell Junctions","volume":"72","author":"Dingwell","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101417_bib61","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nrmicro1972","article-title":"Avoiding the void: cell-to-cell spread of human viruses","volume":"6","author":"Sattentau","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.xcrm.2024.101417_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007054","article-title":"The HSV-1 mechanisms of cell-to-cell spread and fusion are critically dependent on host PTP1B","volume":"14","author":"Carmichael","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.xcrm.2024.101417_bib63","doi-asserted-by":"crossref","first-page":"e00070-19","DOI":"10.1128\/JVI.00070-19","article-title":"Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects","volume":"93","author":"Criscuolo","year":"2019","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101417_bib64","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1128\/JCM.36.11.3198-3204.1998","article-title":"Characterization of a Type-Common Human Recombinant Monoclonal Antibody to Herpes Simplex Virus with High Therapeutic Potential","volume":"36","author":"De Logu","year":"1998","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.xcrm.2024.101417_bib65","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1073\/pnas.91.1.355","article-title":"Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in\u00a0vitro","volume":"91","author":"Burioni","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101417_bib66","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1128\/AAC.05145-11","article-title":"Ocular Distribution, Spectrum of Activity, and In\u00a0Vivo Viral Neutralization of a Fully Humanized Anti-Herpes Simplex Virus IgG Fab Fragment following Topical Application","volume":"56","author":"Berdugo","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.xcrm.2024.101417_bib67","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.antiviral.2017.03.028","article-title":"Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge","volume":"143","author":"Clementi","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.xcrm.2024.101417_bib68","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41577-023-00858-w","article-title":"Antiviral neutralizing antibodies: from in\u00a0vitro to in\u00a0vivo activity","volume":"23","author":"Burton","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2024.101417_bib69","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1099\/0022-1317-18-3-329","article-title":"Genetic Studies with Herpes Simplex Virus Type 1. The Isolation of Temperature-sensitive Mutants, their Arrangement into Complementation Groups and Recombination Analysis Leading to a Linkage Map","volume":"18","author":"Brown","year":"1973","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.xcrm.2024.101417_bib72","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1128\/jvi.70.6.3815-3822.1996","article-title":"Structure-function analysis of soluble forms of herpes simplex virus glycoprotein D","volume":"70","author":"Nicola","year":"1996","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101417_bib74","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4161\/mabs.28808","article-title":"Highly parallel characterization of IgG Fc binding interactions","volume":"6","author":"Boesch","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.xcrm.2024.101417_bib78","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.19809","article-title":"TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau","volume":"5","author":"Rousseaux","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.xcrm.2024.101417_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-2836(85)90320-1","article-title":"Sequence determination and genetic content of the short unique region in the genome of herpes simplex virus type 1","volume":"181","author":"McGeoch","year":"1985","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.xcrm.2024.101417_bib70","doi-asserted-by":"crossref","first-page":"e01156-17","DOI":"10.1128\/JVI.01156-17","article-title":"Role of Herpes Simplex Virus 1 \u03b334.5 in the Regulation of IRF3 Signaling","volume":"91","author":"Manivanh","year":"2017","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101417_bib71","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1099\/0022-1317-74-9-1859","article-title":"In\u00a0vivo characterization of site-directed mutations in the promoter of the herpes simplex virus type 1 latency-associated transcripts","volume":"74","author":"Rader","year":"1993","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.xcrm.2024.101417_bib73","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jim.2017.01.010","article-title":"Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles","volume":"443","author":"Brown","year":"2017","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.xcrm.2024.101417_bib75","article-title":"Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals","volume":"11","author":"Butler","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101417_bib76","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","article-title":"A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples","volume":"366","author":"Ackerman","year":"2011","journal-title":"J.\u00a0Immunol. Methods"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124000405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124000405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T11:00:54Z","timestamp":1733223654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124000405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2666379124000405"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101417","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effector functions are required for broad and potent protection of neonatal mice with antibodies targeting HSV glycoprotein D","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101417","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"101417"}}